• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Progress and hurdles in the development of influenza virus-like particle vaccines for veterinary use

tetano

Editor, Senior Moderator
Clin Exp Vaccine Res. 2014 Jul;3(2):133-9. doi: 10.7774/cevr.2014.3.2.133. Epub 2014 Jun 20.
Progress and hurdles in the development of influenza virus-like particle vaccines for veterinary use.
Lee DH, Park JK, Song CS.
Author information
Abstract

Virus-like particles (VLPs), which resemble infectious virus particles in structure and morphology, have been proposed to provide a new generation of vaccine candidates against various viral infections. As effective immunogens, characterized by high immunogenicity and safety, VLPs have been employed in the development of human influenza vaccines. Recently, several influenza VLP vaccines have been developed for veterinary use and successfully evaluated in swine, canine, duck, and chicken models. These VLP vaccine candidates induced protective immune responses and enabled serological differentiation between vaccinated and infected animals in conjunction with a diagnostic test. Here, we review the current progress of influenza VLP development as a next-generation vaccine technology in the veterinary field and discuss the challenges and future direction of this technology.
KEYWORDS:

Influenza; Vaccines; Veterinary; Virus-like particle

PMID:
25003086
[PubMed]
PMCID:
PMC4083065

Free PMC Article

http://www.ncbi.nlm.nih.gov/pubmed/25003086
 
Back
Top Bottom